Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Placebo Controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects With Primary Sjögren's Syndrome

NCT02334306 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT02334306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02334306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Placebo Controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects With Primary Sjögren's Syndrome
Lead sponsor
MedImmune LLC
Phase
Phase 2
Overall status
Completed
Start date
June 8, 2015
Completion date
August 13, 2018
Enrollment
32 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

primary sjögren's syndrome